Biophytis announces its audited financial results for the year ended December 31, 2021, and provides updates on key operational achievements as well as perspectives for 2022
- Success of Nasdaq IPO in February 2021
- €23.9M of available cash on December 31 2021 and new financing instruments for a total of €42M allowing financial visibility beyond mid 2023
- Strong growth of operational expenses to €26.8M, mainly reflecting clinical program advancement in COVID-19 (COVA) and in sarcopenia (SARA)
- Significant milestones reached for COVA and SARA allowing to prepare for future development of the programs